CNCE - Speculative type of momentum Long from current level

NASDAQ:CNCE   Concert Pharmaceuticals, Inc
CNCE bouncing off from a Long term support & now showing strong upward momentum. In the short term it broken out a downward channel formation. Moneyflow sky rocketed recently. Over all looks a good long opportunity from current level

Trade Criteria
Entry Target Criteria- From current level
Exit Target Criteria- Momentum long , First target- $9.57, Second target- $11
Stop Loss Criteria- $7.93

You can check detailed analysis on CNCE in the trading room/ Executive summary link here-
Time Span- 3:00"
Trade Status: Pending
Trade closed: target reached:
(Note: Trade update is delayed here - To get updated instantly please subscribe to our Newsletter)

Relevant Updates:
January 3rd- Nice trade! Went up & hit second target today. Total profit 23.5% profit in 13 days.

December 29th- Made a higher high, Looking very good as long. Already in 15.7% profit from entry, updating our stop loss criteria to $9.53

December 28th- a small upward move but rapid increase in volume from last couple of days. Already in 13.7% profit from entry & seems it has much higher to go.

December 27th- Updating our stop loss criteria to $8.93

December 23rd- Went up huge 5.87% hitting first target. Closed half of the position at first target with 7.5% profit & updating stoploss to entry price at $8.91 for rest half.

December 22nd- Upmove continued with another 1.81% gain today. Looking very good as long.

December 21st- Nice upward move of 3.08% today. Looking very good as Long.

December 20th- Considered a position early in the morning, price was $8.9. It had a good upward move throughout the day. Looking good as long.

Like what you see? Get full access to our 3X daily members only video/txt alerts & live trading room at

Check out some of our free video examples @

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.